Pain Management in Response to Exparel vs. Standard Bupivicaine
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on
decreasing the amount of consumed pain medications.
Patients will be randomly selected to received either Exparel or standard bupivicaine
injection during surgery. Patients will be followed up to assess pain levels using a visual
pain scale, and to assess how much pain medication was consumed.